KRX 324

Drug Profile

KRX 324

Alternative Names: KRX-324

Latest Information Update: 03 Dec 2007

Price : $50

At a glance

  • Originator Keryx Biopharmaceuticals
  • Class
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 03 Dec 2006 Discontinued - Preclinical for Breast cancer in Israel (unspecified route)
  • 03 Apr 2003 No development reported - Preclinical for Breast cancer in Israel (unspecified route)
  • 03 Oct 2000 Preclinical development for Breast cancer in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top